An advisory panel to the FDA on May 10 unanimously voted to recommend approval of the Opill birth-control pill for over-the-counter availability. A final decision is expected this summer.

They echo other critics who say the drug’s side effects mean patients should have physician supervision while taking the drug.

Read More: National Catholic Register